clentiazem has been researched along with Cardiovascular Stroke in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Latour, JG; Provost, P; Rousseau, G | 1 |
| Caillé, G; Latour, JG; Provost, P; Rousseau, G; Tran, D | 1 |
2 other study(ies) available for clentiazem and Cardiovascular Stroke
| Article | Year |
|---|---|
Sustained myocardial protection by clentiazem (TA-3090) after a 90-minute coronary occlusion and 72 hours of reperfusion in dogs with collateral flow.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Collateral Circulation; Coronary Vessels; Diltiazem; Dogs; Evans Blue; Female; Male; Microspheres; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium | 1993 |
Clentiazem given at reperfusion improves subendocardial reflow and reduces myocardial infarct size in the dog.
Topics: Animals; Calcium Channel Blockers; Collateral Circulation; Coronary Circulation; Diltiazem; Dogs; Female; Hemodynamics; Leukocyte Count; Male; Myocardial Infarction; Myocardial Reperfusion; Neutrophils | 1994 |